BULLETIN V2024-0237
MARVEL BIOSCIENCES CORP. ("MRVL")
BULLETIN TYPE: Private Placement-Non-Brokered, Convertible Debentures
BULLETIN DATE: January 22, 2024
TSX Venture Tier 2 Company
TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced January 19, 2024:
Convertible Debenture $500,000 in outstanding principal amount of unsecured convertible debentures.
Conversion Price: Convertible into 4,166,667 common shares of the Company at $0.12 per share of principal outstanding.
Maturity Date: 3 years from the date of issuance.
Warrants: N/A
Warrant Price: N/A.
Forced Conversion: At the option of the Company, at any time prior to the Maturity Date, may force the conversion of the whole or any portion of the unsecured convertible debentures, if the volume-weighted average trading price for the common shares for 10 trading days equals or exceeds 60 cents per common share, no earlier than 21 days after notice has been provided to the Holder.
Interest rate: 12% per annum, paid annually in arrears.
Number of Placees: 1 placee
Insider / Pro Group Participation:
Placees # of Placee (s) Aggregate # of Shares
Aggregate Existing Insider Involvement: N/A N/A
Aggregate Pro Group Involvement: 1 4,166,667
Aggregate Cash Amount Aggregate #
of Shares Aggregate #
of Warrants
Finder's Fee: N/A N/A N/A
Finder's Warrants Terms: N/A.
The Company issued a news release on January 19, 2024 confirming closing of the private placement.
_______________________________________
|
|
